Evidence map›Paper›PMID 37174087›Full record

ArticleCancers2023

Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.

Chelsea Kotch, Kristina Wagner, J Harris Broad, Eva Dombi, Jane E Minturn, Peter Phillips, Katherine Smith, Yimei Li, Ian N Jacobs, Lisa M Elden and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Neurofibromatosis Type 1 : A General Review.Journal of Korean Neurosurgical Society · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Chelsea KotchDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0001-6561-575X
Kristina WagnerDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
J Harris BroadDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Eva DombiPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Jane E MinturnDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0001-9069-8761
Peter PhillipsDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Katherine SmithDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0003-3559-9538
Yimei LiDepartment of Biostatistics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ian N JacobsDivision of Otolaryngology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Lisa M EldenDivision of Otolaryngology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Michael J FisherDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0003-3408-3839
Jean BelascoDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Children's Hospital of Philadelphia · USNational Cancer Institute · USUniversity of Pennsylvania · US

Funding

Project 4: Secondary Cancers Among NF1 Cancer SurvivorsU54CA196519 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI Yunlong Liu · 2015 to 2026
$26.9M
NCI NIH HHS U54 CA196519
6 · The paper itself

Abstract

Limited therapies exist for neurofibromatosis type 1 (NF1)-associated plexiform neurofibroma (PN). For this reason, the activity of vinblastine (VBL) and methotrexate (MTX) was evaluated in children and young adults with NF1 and PN. Patients ≤ 25 years of age with progressive and/or inoperable NF1-PN received VBL 6 mg/m

Indexed as

chemotherapyclinical trialneurofibromatosis type 1plexiform neurofibroma

Identifiers

PMID37174087
PMCPMC10177272
OpenAlexW4376630941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.